Nordmedicin AB

Active
556807-7233Limited company (AB)Registered 2010STOCKHOLM

Key figures

22 250 kr
Revenue 2025/26
−37,9%
Average annual change 2018/19–2025/26
0200 k400 k600 k800 k2018/192019/202020/212021/222022/232023/242024/252025/26

Key figures

2025/26

Summary: Nordmedicin AB

What kind of company is it?

Nordmedicin AB (org. no. 556807-7233) is a limited company (AB). The company was registered in 2010 and has existed for 16 years. Registered seat: Stockholm. Industry according to Statistics Sweden: general primary medical practice activities (SNI 86211).

How is the company doing financially?

Net sales in financial year 2026 were 22 250 kr. From 2019 to 2026, net sales declined by an average of 37,9 % per year. Financial year 2026 ended with a loss of 37 376 kr. The company was profitable in 5 of the 8 reported financial years. At the end of financial year 2026, total assets were 280 723 kr and equity 265 157 kr (equity ratio 94,5 %).

Where does the data come from and how up to date is it?

Company details and digitally filed annual reports come from the open data of the Swedish Companies Registration Office (Bolagsverket) and the industry code from Statistics Sweden (CC BY 2.5 SE); bolagsprofil.se updates them daily. The latest annual report is signed by one person. Data as of 2026-11-16. Changes, averages and ratios are calculated by bolagsprofil.se from open data and are not an official assessment.

Dividend

from the annual report
2022/23

Proposed dividend 90 000 kr.

History
2022/2390 000 kr
2019/20150 000 kr
Summary of annual reports2019–2026
2021/222022/232023/242024/252025/26
Sales revenue00121 000022 250
Profit for the reporting year2 16223 44361 053−73 177−37 376
Retained earnings of previous periods—————
Total assets466 312433 098473 345319 296280 723
Total liabilities85 09828 44197 63516 76315 566
Total equity381 214404 657375 710302 533265 157
Employees—————
Proposed dividend—90 000———

A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.